NanoViricides is a clinical-stage biopharmaceutical company developing antiviral drugs using its proprietary nanoviricide platform technology, which uses self-assembling polymers to directly attack virus particles by targeting conserved host-binding sites that viruses cannot escape without losing infectivity. The company's lead candidate, NV-387, is a broad-spectrum antiviral formulated in multiple delivery forms (oral, injectable, inhalation) with demonstrated efficacy across respiratory viruses, orthopoxviruses, and measles, supported by additional pipeline programs targeting herpes, HIV, and approximately forty viral indications total. NanoViricides currently generates no revenue but plans to monetize through milestone payments and royalties from out-licensing partnerships, direct commercialization of select indications, and government contracts for biodefense applications, while operating integrated manufacturing and R&D facilities that support clinical development and provide manufacturing capability.